Kyal and Ben discuss the repercussions of regulatory changes affecting peptide vendors. They highlight the risks of compromised quality and the importance of thorough testing for injectable peptides. The conversation delves into the need for human evidence and calls for funding research instead of banning these beneficial compounds.
